{
  "abstract": "Background: Trastuzumab deruxtecan (T-DXd) is effective for advanced breast cancer but is associated with interstitial lung disease (ILD). The clinical relevance of baseline interstitial lung abnormalities (ILAs), including subtle equivocal findings, remains unclear.\n\nMethods: This retrospective cohort study included consecutive patients with advanced or recurrent breast cancer who initiated T-DXd at a tertiary hospital in Japan between June 2020 and May 2025. Baseline CT before T-DXd initiation was reviewed for ILAs and classified as no ILA, equivocal ILA, or definite ILA. The cumulative incidence of T-DXd-related ILD was estimated using a competing-risk approach.\n\nResults: Among 156 patients, baseline ILAs were identified in 50 patients: 21 with equivocal ILA and 29 with definite ILA. T-DXd-related ILD occurred in 31 patients (20%), including 19 of 50 patients (38%) in the ILA group and 12 of 106 patients (11%) in the non-ILA group. Baseline ILA was associated with a higher cumulative incidence of T-DXd-related ILD (subdistribution hazard ratio, 3.56; 95% CI, 1.63-7.78; P = .001). No significant difference in T-DXd-related ILD risk was detected between the equivocal and definite ILA groups. This association remained consistent in the <1.5-mm CT subgroup. No significant differences in progression-free or overall survival were observed according to baseline ILA status. Among patients with baseline ILA, 33 of 50 had ILAs first detected during prior systemic anticancer therapy.\n\nConclusions: Baseline ILAs, including equivocal findings, were associated with an increased risk of T-DXd-related ILD. ILAs were frequently first detected during prior systemic anticancer therapy before T-DXd initiation.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "name": "Tomoaki Nakamura",
      "orcid": "0000-0002-4248-8601"
    },
    {
      "name": "Naoki Murata",
      "orcid": "0009-0002-2447-5636"
    },
    {
      "name": "Yukiko Hibino"
    },
    {
      "name": "Clara So",
      "orcid": "0000-0001-7802-078X"
    },
    {
      "name": "Atsushi Kitamura"
    },
    {
      "name": "Yutaka Tomishima",
      "orcid": "0000-0003-1615-5245"
    },
    {
      "name": "Torahiko Jinta"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a94592wv9p6zv.bib",
  "cited_by": 0,
  "doi": "10.1093/oncolo/oyag420",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13716483/",
  "id": "a94592wv9p6zv",
  "issns": [
    "1083-7159",
    "1549-490X"
  ],
  "landing_url": "https://doi.org/10.1093/oncolo/oyag420",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "AcademicSubjects/MED00010"
    ],
    [
      "heading",
      "Breast Cancer"
    ],
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2740|Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis"
    ]
  ],
  "openalex": "W7223046834",
  "pdf_url": "https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyag420/72124908/oyag420.pdf",
  "pmcid": "PMC13716483",
  "pmid": "42897999",
  "published": "2026-10-19",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/a94592wv9p6zv.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T12:23:25Z",
      "native_id": "PMC13716483",
      "source": "pmc",
      "url": "https://doi.org/10.1093/oncolo/oyag420"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis",
      "subfield": "general"
    }
  ],
  "title": "Equivocal and definite interstitial lung abnormalities as risk factors for trastuzumab deruxtecan-related interstitial lung disease in breast cancer",
  "title_text": "Equivocal and definite interstitial lung abnormalities as risk factors for trastuzumab deruxtecan-related interstitial lung disease in breast cancer",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:23:25Z",
  "url": "https://research.draconitic.com/paper/a94592wv9p6zv",
  "venue": "The Oncologist",
  "versions": []
}